OncoMatch/Clinical Trials/NCT06339619
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
Is NCT06339619 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Adebrelimab and Apatinib for locally advanced or metastatic esophageal squamous cell carcinoma.
Treatment: Adebrelimab · Apatinib · Tegafur — The goal of this single-arm study is to explore the efficacy and safety of Adebrelimab in combination with Apatinib and Tegafur for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma that has failed first-line standard treatment with PD-1 inhibitors in combination with chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage III, DISTANT METASTASIS (AJCC 8th edition)
locally advanced unresectable or distant metastasis (according to AJCC 8th edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: immunotherapy combined with chemotherapy — first-line
Patients who have failed first-line immunotherapy combined with chemotherapy
Cannot have received: (Adebrelimab, Apatinib, Tegafur)
Patients who had previously received treament of Adebrelimab, Apatinib or Tegafur
Cannot have received: Chinese medicine anti-tumor treatment
Used Chinese medicine anti-tumor treatment within 2 weeks
Cannot have received: other anti-tumor therapy
Received other anti-tumor therapy within 4 weeks, including but not limited to chemotherapy, radiotherapy, and targeted therapy
Lab requirements
Blood counts
ANC≥1.5×10^9/L; PLT≥100×10^9/L; Hb≥90 g/L; Serum albumin ≥30 g/L
Kidney function
Cr ≤1.5×ULN, or creatinine clearance ≥50mL/min as calculated by the Cockcroft-Gault formula; Patients with urinary protein ≥++ should undergo further 24-hour quantitative detection of urinary protein, and the detection result should be<1.0g
Liver function
TBIL≤1.5×ULN; ALT and AST≤2.5 x ULN; For patients with liver metastases, ALT and AST≤5×ULN
Cardiac function
QTcF>470 ms; history of congenital long QT syndrome; history of any clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes); left ventricular ejection fraction (LVEF) <50%
The functional level of the organ must meet the following requirements. (1) ANC≥1.5×10^9/L; (2) PLT≥100×10^9/L; (3) Hb≥90 g/L; (4) Serum albumin ≥30 g/L; (5) TBIL≤1.5×ULN; ALT and AST≤2.5 x ULN; For patients with liver metastases, ALT and AST≤5×ULN; (6) Cr ≤1.5×ULN, or creatinine clearance ≥50mL/min as calculated by the Cockcroft-Gault formula; (7) Patients with urinary protein ≥++ should undergo further 24-hour quantitative detection of urinary protein, and the detection result should be<1.0g. Fridericia-corrected QT interval (QTcF)>470 ms; history of congenital long QT syndrome; history of any clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes); left ventricular ejection fraction (LVEF) <50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06339619 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior , Chinese medicine anti-tumor treatment, other anti-tumor therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or DISTANT METASTASIS is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages